Abstracts tagged "tocilizumab and vasculitis"

Abstract Number: 1836 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial
Robert Spiera¹, Sebastian Unizony ², Min Bao ³, Yves Luder ⁴, Páris Sidiropoulos ³, Jian Han ³, Jinglan Pei ³ and John Stone ², ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Genentech, South San Francisco, CA, ⁴F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: GiACTA, a randomized, double-blind, placebo (PBO)–controlled study, demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA).1 Growing evidence…
Abstract Number: 2665 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice
Sebastian Unizony¹, Robert Spiera ², Jinglan Pei ³, Páris Sidiropoulos ³, Jennie Best ⁴ and John Stone ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Genentech, South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Approximately 50% of patients with giant cell arteritis (GCA) also have polymyalgia rheumatica (PMR) symptoms.1 The purpose of this study was to determine whether…
Abstract Number: 780 • 2017 ACR/ARHP Annual Meeting
Short and Long-Term Follow-up with Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 49 Patients of Clinical Practice
Lucia C. Domínguez-Casas¹, Javier Loricera¹, Jose L. Hernández², Santos Castañeda³, Vicente Aldasoro⁴, María Varela-García⁵, Rosario Ibañez-Bosch⁵, Antonio Mera⁶, Eva Pérez-Pampin⁶, Alicia Humbría⁷, Jaime Calvo-Alén⁸, Elena Aurrecoechea⁹, Javier Narváez¹⁰, Amalia Sánchez-Andrade¹¹, Paloma Vela¹², Elvira Diez Alvarez¹³, Clara Moriano¹⁴, Cristina Mata¹⁵, Pau Lluch¹⁶, Concepción Moll¹⁷, Íñigo Hernández-Rodríguez¹⁸, Vanesa Calvo-Río¹, José Andrés Román-Ivorra¹⁹, Carlos Vazquez²⁰, Alfonso Corrales¹, MC Gonzalez-Vela²¹, Francisco Ortiz-Sanjuán²², Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Miguel Angel González-Gay²³ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario La Princesa. IIS-IP. Madrid. Spain, Madrid, Spain, ⁴Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁵Rheumatology, Complejo Hospitalario de Navarra. Navarra. Spain, Navarra, Spain, ⁶Rheumatology, Complejo Hospitalario Universitario de Santiago. Galicia. Spain, Santiago de Compostela, Spain, ⁷Rheumatology, Hospital Universitario La Princesa. IIS-IP. Madrid. Spain, Madrid, Spain, ⁸Rheumatology, Hospital de Sierrallana. Torrelavega. Cantabria. Spain, Alava, Spain, ⁹Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, ¹⁰Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ¹¹Hospital Universitario Lucus Augusti. Lugo. Spain, Lugo, Spain, ¹²Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ¹³Complejo Asistencial Universitario de León. León. Spain, León, Spain, ¹⁴Rheumatology, Complejo Asistencial Universitario de León. León. Spain, Leon, Spain, ¹⁵Rheumatology, Hospital de Laredo. Laredo. Spain, Laredo, Spain, ¹⁶Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ¹⁷Rheumatology., Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ¹⁸Rheumatology, CHUVI Vigo. Galicia. Spain, Vigo, Spain, ¹⁹Rheumatology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ²⁰Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²¹Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²²Rheumatology., Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ²³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Johannesburg, South Africa
Background/Purpose: Randomized clinical trial has shown the efficacy of tocilizumab (TCZ) in Giant cell arteritis (GCA). However this data are of selected cases of clinical…
Abstract Number: 805 • 2017 ACR/ARHP Annual Meeting
Serological Immune-Inflammatory Markers of the First RCT about Tocilizumab to Treat Giant Cell Arteritis
Andrea Gloor¹, Daniel Yerly², Stefan Kuchen³, Sabine Adler⁴, Stephan Reichenbach¹, Michael Seitz⁵ and Peter M. Villiger⁶, ¹Rheumatology, University hospital, Bern, Switzerland, ²Rheumatology, Uiversity hospital, Bern, Switzerland, ³Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, MD, Switzerland, ⁴Rheumatology, University Hospital Bern, Bern, Switzerland, ⁵Rheumatology, Clinical Immunology & Allergology, University Hospital, Bern, Switzerland, ⁶Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) about tocilizumab (TCZ) in giant cell arteritis (GCA) showed…
Abstract Number: 867 • 2016 ACR/ARHP Annual Meeting
Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137)
Sabine Adler¹, Stephan Reichenbach², Stefan Kuchen³, Felix Wermelinger⁴, Diana Dan⁴, Michael Seitz⁴ and Peter M. Villiger⁴, ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland, ⁴Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose:
Abstract Number: 1989 • 2015 ACR/ARHP Annual Meeting
Treatment of Refractory Non-Infectious Aortitis: Tocilizumab Compared to Antitnf Alfa Agents. Multicenter Study of 44 Patients
Montserrat Santos-Gómez¹, Javier Loricera¹, Ricardo Blanco¹, Jose L. Hernández², Santos Castañeda³, Norberto Ortego-Centeno⁴, M. Enriqueta Peiró¹, Paz Collado⁵, Sheila Melchor⁶, Antonio Mera⁷, Eva Pérez-Pampin⁸, Esteban Rubio Romero⁹, Jaime Calvo-Alen¹⁰, Elena Aurrecoechea¹¹, Iñigo Rúa-Figueroa¹², Mauricio Minguez¹³, Gabriel Herrero-Beaumont¹⁴, Beatriz Bravo¹⁵, José Rosas¹⁶, Javier Narváez¹⁷, Javier Calvo¹⁸, Rafael Ariza-Ariza¹⁹, Mercedes Freire²⁰, Pablo Lluch Mesquida²¹, Cristina Mata²², Eva Galindez-Agirregoikoa²³, Juan María Blanco Madrigal²³, Amalia Sánchez²⁴, José Salvatierra²⁵, Vanesa Calvo-Río¹, Carmen Gonzalez-Vela²⁶, Natalia Palmou¹, Leyre Riancho-Zarrabeitia¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario de la Princesa, Madrid, Spain, ⁴Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ⁵Rheumatology, Pediatric Rheumatology Unit, Hospital Universitario Severo Ochoa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Universitario de Santiago de Compostela, La Coruña, Spain, ⁸Rheumatology, Hospital Universitario de Santiago de Compostela, La coruña, Spain, ⁹Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁰Rheumatology Division, Hospital de Sierrallana, Torrelavega, Spain, ¹¹Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ¹²Rheumatology, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canarias, Spain, ¹³Department of Rheumatology, Hospital Universitario San Juan, Alicante, Spain, ¹⁴Department of Osteoarticular Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ¹⁵Pediatric rheumatology, Hospital Virgen de las Nieves, Granada, Spain, ¹⁶Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁸Rheumatology, Hospital General Consorcio de Valencia, Valencia, Spain, ¹⁹Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ²⁰Rheumatology, Complejo Hospitalario Universitario de A Coruña, La Coruna, Spain, ²¹Hospital Mateu Orfila, Mahón (Menorca), Spain, ²²Rheumatology, Hospital de Sierrallana, Laredo, Spain, ²³Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ²⁴Hospital Lucus Augusti, Lugo, Spain, ²⁵Hospital Universitario de San Cecilio, Granada, Spain, ²⁶Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Aortitis is often refractory to conventional immunosuppressive (IS) therapy. The use of biological therapy, such as tocilizumab (TCZ) and anti-TNFα agents have been…
Abstract Number: 814 • 2014 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis: Multicenter Open-Label Study of 22 Patients
Montserrat Santos-Gómez¹, Javier Loricera¹, Ricardo Blanco¹, Jose L. Hernández², Antonio Mera³, Eva Pérez-Pampin⁴, M. Enriqueta Peiró¹, Santos Castañeda-Sanz⁵, Alicia Humbría⁶, Jaime Calvo-Alen⁷, Elena Aurrecoechea⁸, Javier Narváez⁹, Amalia Sánchez-Andrade¹⁰, Paloma Vela¹¹, Elvira Díez Álvarez¹², Cristina Mata¹³, Pablo Lluch Mesquida¹⁴, Concepcion Moll Tuduri¹⁴, Vanesa Calvo-Río¹, Francisco Ortiz-Sanjuán¹, Trinitario Pina Murcia¹⁵, Carmen Gonzalez-Vela¹⁶, Leyre Riancho-Zarrabeitia¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Clínico Universitario de Santiago de Compostela. Spain, Santiago de Compostela, Spain, ⁴Rheumatology, Hospital Clínico Universitario de Santiago de Compostela. Spain, Santiago de Compostela, Spain, ⁵Rheumatology, Hospital Universitario de La Princesa. Madrid. Spain, Madrid, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa. IIS-Princesa, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁸Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ¹⁰Rheumatology, Hospital Universitario Lucus Augusti. Lugo. Spain, Lugo, Spain, ¹¹Rheumatology, Hospital General de Alicante. Spain, Alicante, Spain, ¹²Rheumatology, Hospital de León. Spain, León, Spain, ¹³Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ¹⁴Hospital Mateu Orfila. Menorca. Spain, Mahón (Menorca), Spain, ¹⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ¹⁶Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose Giant cell arteritis (GCA) is a primary vasculitis that involves the aorta and its major branches. It usually affects people aged more than 50…
Abstract Number: 1686 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Refractory Takayasu Arteritis: a Case Series and Updated Literature Review.²
Noemie Abisror¹, Arsene Mekinian², Christian Lavigne³, Marie Anne Vandenhende⁴, Michael Soussan⁵ and Olivier Fain¹, ¹Internal Medicine, Jean Verdier Hospital, Bondy, France, ²Internal Medicine, Jean Verdier Hospital, Bondy, FL, France, ³Internal Medicine, Angers, France, ⁴Internal Medicine, Bordeaux, France, ⁵Nuclear Medicine, Avicennes Hospital, Bobigny, France
Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review.Background/Purpose: The aim of this study is to analyze the efficacy and tolerance of…
Abstract Number: 1687 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Refractory Aortitis: A Multicenter Study Of 13 Patients
Javier Loricera¹, Ricardo Blanco², Santos Castañeda³, Alicia Humbría⁴, Sheila Melchor⁵, Jaime Calvo-Alen⁶, Elena Aurrecoechea⁶, Íñigo Rúa-Figueroa⁷, Norberto Ortego⁸, Mauricio Mínguez⁹, Gabriel Herrero-Beaumont¹⁰, Beatriz Bravo¹¹, Jose Rosas¹², Javier Narvaez¹³, Javier Calvo¹⁴, Rafael Ariza¹⁵, Mercedes Freire¹⁶, M. Enriqueta Peiró¹, Vanesa Calvo-Río¹, Francisco Ortiz-Sanjuán² and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ³Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS-Princesa, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario 12 de Octubre. Madrid, MADRID, Spain, ⁶Rheumatology, Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ⁷Rheumatology, Hospital Universitario Dr Negrín. Las Palmas, Las Palmas de Gran Canaria, Spain, ⁸Autoimmune Disease Unit, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁹Rheumatology, Hospital Universitario San Juan. Alicante, Alicante, Spain, ¹⁰Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz, Madrid, Spain, ¹¹Pediatric rheumatology, Hospital Virgen de las Nieves. Granada, Granada, Spain, ¹²Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ¹³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Rheumatology, Consorcio Hospital General Universitario. Valencia, Valencia, Spain, ¹⁵Rheumatology, University Hospital Virgen Macarena.Sevilla, Sevilla, Spain, ¹⁶Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain
Background/Purpose: Aortitis can occur alone or associated with other conditions. It is often refractory to standard immunosuppressive therapy. IL-6 has been implicated in the mechanisms…
Abstract Number: 2360 • 2012 ACR/ARHP Annual Meeting
Prevalence, Management and Outcomes of PET Positive Large Vessel Vasculitis in Difficult to Treat PMR and GCA Patients
Pravin Patil¹, Shaifali Jain², Katerina Achilleos³, Tochukwu Adizie¹, Mark Williams¹, Matthew Tam² and Bhaskar Dasgupta⁴, ¹Rheumatology, Southend University Hospital, Westcliff on sea, United Kingdom, ²Radiology, Southend University Hospital, Westcliff on sea, United Kingdom, ³Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, ⁴Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Background/Purpose: Management of PMR and GCA can be challenging in patients with persistently elevated inflammatory markers, prominent constitutional symptoms and inadequate steroid response. We undertook…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].